Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies.
about
A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinibUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Practical management of patients with chronic myeloid leukemia.Ageing is a risk factor in imatinib mesylate cardiotoxicityCardiotoxicity of molecularly targeted agentsImatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review.Chemotherapy-related cardiotoxicity.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity.Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase.A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat.Effects of acute and chronic sunitinib treatment on cardiac function and calcium/calmodulin-dependent protein kinase II.Cardiovascular differentiation of imatinib and bosutinib in the rat.
P2860
Q28476189-FDF4BE58-6256-4EF5-A13B-F12BD9062494Q33408049-216FF4EC-1DFD-4E90-8519-E7FBDA7CC99FQ33849146-750DFB12-76BA-41A8-A6A9-513402F71FC9Q34548719-FD17428B-7AC2-4895-98C8-40536E7B2B0AQ35878459-1AEEB7EC-59B5-4974-9181-5F5C1BEED393Q36288883-4521BAA3-E814-41A3-85D1-197975940ADEQ36316309-02E2E8C4-8E12-42E4-89C7-53EF4118205FQ36891574-3D4C6E68-FF74-41B9-8F58-8D7FEA85D801Q37033345-B043FD91-19FC-4EDE-A6C0-FE7F4AACB331Q37537655-1174CF67-875C-48F7-A457-86BF3BC9ED9EQ37669202-40ED547A-540E-4187-A39E-CA434619C8B3Q37926954-5D4867AA-2FB4-4702-BF58-8C6DDAF8F964Q38076114-90391DC5-12E6-4EC7-AB79-8750BD8703A3Q38088974-79609B7A-47E3-4B06-9331-C395F5D85B6CQ38501976-5BB57ACD-2FEC-445E-80AF-D49C99D44520Q38707841-1BB895F9-4F26-4D8C-826E-239D42920F03Q38742779-FEE6D910-8B6F-4864-BBB2-32B9318F2F89Q39186183-04565F02-9189-447C-A8FD-FEFC66AC5CD9Q42717840-5029CBBF-2BB0-4E93-B7BC-A93E083DF6A4Q42726669-5AD7D4D9-B5B9-43A3-9C4E-01B7A8591674Q43019107-F0AB0369-BE5C-4BAB-953A-3817777608ECQ51191703-3D373964-56AE-47CF-B797-CA059D66039D
P2860
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Imatinib does not induce cardi ...... ations in preclinical studies.
@en
Imatinib does not induce cardi ...... ations in preclinical studies.
@nl
type
label
Imatinib does not induce cardi ...... ations in preclinical studies.
@en
Imatinib does not induce cardi ...... ations in preclinical studies.
@nl
prefLabel
Imatinib does not induce cardi ...... ations in preclinical studies.
@en
Imatinib does not induce cardi ...... ations in preclinical studies.
@nl
P2093
P1433
P1476
Imatinib does not induce cardi ...... ations in preclinical studies.
@en
P2093
Anja Nussher
Armin Wolf
Christian Trendelenburg
Daniel Robert Roth
Danielle Roman
David Ledieu
Elke Persohn
Estelle Marrer
Francois Pognan
Gilles-Jacques Rivière
P304
P356
10.1016/J.LEUKRES.2010.01.004
P577
2010-01-31T00:00:00Z